Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2025 · 10-Q
Revenue$1.03M$1.03M+67.2% vs Q3 2024 Net Income-$509.94K-$509.94KN/M vs Q3 2024 EPS Diluted-$0.33-$0.33N/M vs Q3 2024 Operating Income-$544,734N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-53.0%+28.3 pt vs Q3 2024
Net margin-49.7%+21.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end